JP2024538091A5 - - Google Patents

Info

Publication number
JP2024538091A5
JP2024538091A5 JP2024522237A JP2024522237A JP2024538091A5 JP 2024538091 A5 JP2024538091 A5 JP 2024538091A5 JP 2024522237 A JP2024522237 A JP 2024522237A JP 2024522237 A JP2024522237 A JP 2024522237A JP 2024538091 A5 JP2024538091 A5 JP 2024538091A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
approximately
arginine
poloxamer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024522237A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538091A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/078097 external-priority patent/WO2023064886A1/en
Publication of JP2024538091A publication Critical patent/JP2024538091A/ja
Publication of JP2024538091A5 publication Critical patent/JP2024538091A5/ja
Pending legal-status Critical Current

Links

JP2024522237A 2021-10-15 2022-10-14 第ｖｉｉｉ因子キメラタンパク質の製剤およびその使用 Pending JP2024538091A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163256432P 2021-10-15 2021-10-15
US63/256,432 2021-10-15
PCT/US2022/078097 WO2023064886A1 (en) 2021-10-15 2022-10-14 Formulations of factor viii chimeric proteins and uses thereof

Publications (2)

Publication Number Publication Date
JP2024538091A JP2024538091A (ja) 2024-10-18
JP2024538091A5 true JP2024538091A5 (enExample) 2025-10-21

Family

ID=84362012

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024522237A Pending JP2024538091A (ja) 2021-10-15 2022-10-14 第ｖｉｉｉ因子キメラタンパク質の製剤およびその使用

Country Status (12)

Country Link
US (1) US20240358800A1 (enExample)
EP (1) EP4415693B1 (enExample)
JP (1) JP2024538091A (enExample)
KR (1) KR20240082408A (enExample)
CN (1) CN118103034A (enExample)
AU (1) AU2022366974A1 (enExample)
CA (1) CA3229979A1 (enExample)
CO (1) CO2024004211A2 (enExample)
IL (1) IL311969A (enExample)
MX (1) MX2024004494A (enExample)
TW (1) TW202334244A (enExample)
WO (1) WO2023064886A1 (enExample)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2124690C (en) * 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
PL3793588T3 (pl) * 2018-05-18 2025-09-01 Bioverativ Therapeutics Inc. Sposoby leczenia hemofilii a

Similar Documents

Publication Publication Date Title
JP7168451B2 (ja) 二重特異性抗体コンストラクトを含む医薬組成物
JP2020138981A5 (enExample)
AU2013255413C1 (en) Pharmaceutical formulations of TNF-alpha antibodies
JP2024099682A5 (enExample)
JP2022518695A5 (enExample)
TW201424748A (zh) 高濃度抗體及蛋白質調配物
JP2009524595A5 (enExample)
JP2022151814A5 (enExample)
JP2024540377A5 (enExample)
JP2024538091A5 (enExample)
JP2024522855A5 (enExample)
JP2022515721A5 (enExample)
US12030916B2 (en) Compositions, methods, and systems for orally administrable affinity-based protein
US20250152706A1 (en) Compositions for oral delivery of biotherapeutics
WO2024120458A1 (zh) TACI-Fc融合蛋白液体药物制剂
TWI775827B (zh) 水性製劑及裝入注射器之水性製劑以及抗體蛋白去凝集劑及抗體蛋白去凝集方法
JP2019147787A (ja) ポリペプチドの凝集化抑制方法
JPS6089433A (ja) 制癌作用物質複合体の製造法
WO2026026827A1 (zh) 抗il-5抗体制剂及其制备方法
US20230025806A1 (en) Stable compositions of fc multimers
RU2024121587A (ru) ЖИДКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ СЛИТЫЙ БЕЛОК, ВКЛЮЧАЮЩИЙ α-ГАЛАКТОЗИДАЗУ A
WO2026067668A1 (zh) 抗il-17抗体制剂及其制备方法和应用
WO2026067821A1 (zh) 一种抗pd-1抗体制剂及其制备方法和用途
BR112018014986B1 (pt) Composição farmacêutica compreendendo construções de anticorpo biespecíficas
HK1210794B (zh) 抗体和蛋白质制剂